Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408576 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
NCT01408576 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 1,250 participants.
The verdict
NCT01408576, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
Study Summary
The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)
Interventions
- DRUG Epratuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408576
The ClinicalTrials.gov registry entry for NCT01408576 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epratuzumab is the first listed.
NCT01408576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01408576 about?
NCT01408576 is a clinical study titled "Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus". The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)
What is the current status of trial NCT01408576?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2011-07. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01408576?
The interventions under investigation include: Epratuzumab (DRUG).
Who is sponsoring clinical trial NCT01408576?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.